long intergenic non-protein coding RNA 1586Genealiases: []
Q-omics provides the consensus-scored LINC01586 profile across patient tissues and cancer cell-line models. LINC01586 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in READ. Among the 18 cancer types available for tumor–normal comparison, LINC01586 is differentially expressed in 4, with the highest sampling consensus in THCA. Additionally, LINC01586 RNA expression shows 15,023 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight READ, THCA, and TGCT as cancer lineages where LINC01586 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01586 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01586 survival associations across molecular data types. LINC01586 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01586 RNA expression–survival associations across cancer types. High LINC01586 expression shows unfavorable associations in READ and MESO, but favorable associations in PAAD, CHOL, LUSC and LGG. The READ Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify READ as the clearest survival context for LINC01586 RNA expression.
This table summarizes LINC01586 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01586. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01586 shows lower tumor expression in THCA, COAD, BRCA and LUAD. The THCA box plot shows higher LINC01586 RNA expression in normal versus tumor tissue (log2 FC = −2.590, t-test p < 0.001).
This table shows molecular features associated with LINC01586 in patient tissues and cancer cell lines. In patient samples, LINC01586 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
